At the 2019 CIMT Annual Meeting, preclinical study data have been presented, as DCprime was able to demonstrate that human antigen presenting cells (APCs) efficiently process DCP-001 through phagocytosis. These in vitro data suggest that in vivo, upon intradermal injection, DCP-001 will induce a strong inflammatory response, and is ingested by both resident and attracted host APCs, which subsequently prime tumor-reactive T cells. These data support the proposed mode of action whereby host APCs present DCP-001 antigens to the host immune system following intradermal vaccination.
For more information see http://www.professionalabstracts.com/cimt2019/Iplanner/#/presentation/326